COVID-19 Results Briefing

Greece

July 19, 2022

This document contains summary information on the latest projections from the IHME model on COVID-19 in Greece. The model was run on July 15, 2022, with data through July 10, 2022.

Current situation

- Daily infections in the last week increased to 51,000 per day on average compared to 50,000 the week before (Figure 1.1). Daily hospital census in the last week (through July 10) increased to 2,400 per day on average compared to 2,000 the week before.
- Daily reported cases in the last week increased to 17,000 per day on average compared to 14,000 the week before (Figure 2.1).
- Reported deaths due to COVID-19 in the last week increased to 27 per day on average compared to 18 the week before (Figure 3.1).
- Total deaths due to COVID-19 in the last week increased to 30 per day on average compared to 21 the week before (Figure 3.1). This makes COVID-19 the number three cause of death in Greece this week (Table 1). Estimated total daily deaths due to COVID-19 in the past week were 1.1 times larger than the reported number of deaths.
- The daily rate of reported deaths due to COVID-19 is greater than 4 per million in two countries (Figure 4.1).
- The daily rate of total deaths due to COVID-19 is greater than 4 per million in three countries (Figure 4.2).
- We estimate that 80% of people in Greece have been infected at least once as of July 11 (Figure 6.1). Effective R, computed using cases, hospitalizations, and deaths, is greater than 1 in 43 countries and 35 subnational locations. Effective R in Greece was 1.1 on June 30 (Figure 7.1).
- Based on the GISAID and various national databases, combined with our variant spread model, we estimate the current prevalence of variants of concern (Figures 8.1-8.5). We estimate that the Alpha variant is circulating in 51 countries and 59 subnational locations, that the Beta variant is circulating in 29 countries and 13 subnational locations, that the Delta variant is circulating in 51 countries and 60 subnational locations, that the Gamma variant is circulating in 26 countries and 22 subnational locations, and that the Omicron variant is circulating in 51 countries and 60 subnational locations.

Trends in drivers of transmission

- Mobility last week was 20% higher than the pre-COVID-19 baseline (Figure 10.1). Mobility was lower than 15% of baseline in one country (Figure 11.1).
- As of June 24, in the COVID-19 Trends and Impact Survey, 20% of people self-reported that they always wore a mask when leaving their home compared to 20% the previous week (Figure 12.1).
- There were 829 diagnostic tests per 100,000 people on July 11 (Figure 14.1).
- As of July 11, 24 countries and 57 subnational locations have reached 70% or more of the population who have received at least one vaccine dose, and 20 countries and 54 subnational locations have reached 70% or more of the population who are fully vaccinated (Figures 16.1 and 16.2). 77% of people in Greece have received at least one vaccine dose, and 72% are fully vaccinated.
- As of June 24, 2022, three percent of the population in Greece say they would accept a vaccine for COVID-19 but have not yet been vaccinated.
- In our current reference scenario, we expect that 7.9 million people will be vaccinated with at least one dose by November 1 (Figure 18.1). We expect that 72% of the population will be fully vaccinated by November 1.
Projections and scenarios

We produce three scenarios when projecting COVID-19. The reference scenario is our forecast of what we think is most likely to happen:

- Vaccines are distributed at the expected pace. Brand- and variant-specific vaccine efficacy is updated using the latest available information from peer-reviewed publications and other reports.
- Future mask use will decline to 50% of the minimum level it reached between January 1, 2021, and May 1, 2022. This decline begins after the last observed data point in each location and transitions linearly to the minimum over a period of six weeks.
- Mobility increases as vaccine coverage increases.
- 80% of those who are fully vaccinated (two doses for most vaccines, or one dose for Johnson & Johnson) receive an additional dose six months after becoming fully vaccinated, and 80% of those who receive an additional dose receive a second additional dose six months later.
- Antiviral utilization for COVID-19 risk prevention has reached 80% in high-risk populations and 50% in low-risk populations between March 1, 2022, and June 1, 2022. This applies in high-income countries, but not low- and middle-income countries, and this rollout assumption follows a similar pattern to global vaccine rollouts.

The 80% mask use scenario makes all the same assumptions as the reference scenario but assumes all locations reach 80% mask use within seven days. If a location currently has higher than 80% use, mask use remains at the current level.

The antiviral access scenario makes all the same assumptions as the reference scenario but assumes globally distributed antivirals and extends coverage to all low- and middle-income countries between August 15, 2022, and September 15, 2022.

Infections

- Daily estimated infections in the reference scenario will decline to 11,120 by September 29, 2022 (Figure 20.1).
- Daily estimated infections in the 80% mask use scenario will decline to 2,710 by September 29, 2022 (Figure 20.1).
- Daily estimated infections in the antiviral access scenario will decline to 11,120 by September 29, 2022 (Figure 20.1).

Cases

- Daily estimated cases in the reference scenario will rise to 17,960 by July 12, 2022 (Figure 20.2).
- Daily estimated cases in the 80% mask use scenario will decline to 650 by October 13, 2022 (Figure 20.2).
- Daily estimated cases in the antiviral access scenario will rise to 17,960 by July 12, 2022 (Figure 20.2).

Hospitalizations

- Daily hospital census in the reference scenario will rise to 2,840 by July 22, 2022 (Figure 20.3). At some point from July through November 1, six countries will have high or extreme stress on hospital beds (Figure 22.1). At some point from July through November 1, 17 countries will have high or extreme stress on intensive care unit (ICU) capacity (Figure 23.1).
- Daily hospital census in the 80% mask use scenario will rise to 2,760 by July 19, 2022 (Figure 20.3).
- Daily hospital census in the antiviral access scenario will rise to 2,840 by July 22, 2022 (Figure 20.3).
Deaths

- In our **reference scenario**, our model projects 34,000 cumulative reported deaths due to COVID-19 on November 1. This represents 3,200 additional deaths from July 11 to November 1. Daily reported COVID-19 deaths in the **reference scenario** will rise to 50 by August 4, 2022 (Figure 20.4).
- Under our **reference scenario**, our model projects 38,000 cumulative total deaths due to COVID-19 on November 1. This represents 3,600 additional deaths from July 11 to November 1 (Figure 20.5).
- In our **80% mask use scenario**, our model projects 32,000 cumulative reported deaths due to COVID-19 on November 1. This represents 1,900 additional deaths from July 11 to November 1. Daily reported COVID-19 deaths in the **80% mask use scenario** will rise to 50 by July 31, 2022 (Figure 20.4).
- In our **antiviral access scenario**, our model projects 34,000 cumulative reported deaths due to COVID-19 on November 1. This represents 3,200 additional deaths from July 11 to November 1. Daily reported COVID-19 deaths in the **antiviral access scenario** will rise to 50 by August 4, 2022 (Figure 20.4).

- Figure 21.1 compares our reference scenario forecasts to other publicly archived models. Forecasts are widely divergent.
Model updates

This month, we have made two alterations to our reference scenario assumptions and one alteration to our antiviral scenario assumptions in the model. First, in the reference scenario, we included an estimate for an additional vaccination dose (second booster). As was previously done with the first booster, we assumed 80% of those who are fully vaccinated (two doses for most vaccines, or one dose for Johnson & Johnson), receive an additional dose six months after becoming fully vaccinated. In this model, we assume 80% of those who receive an additional dose (first booster) receive a second additional dose (second booster) 4-6 months later. Distribution assumptions were time-corrected based on reported data. We estimated each vaccination course using the doses administered in the previous course, taking into account the number of doses available based on manufacturer distribution data. We updated this process to estimate supply and demand on a daily basis rather than periodically.

Second, we expect the recent rollout of Paxlovid treatments in high-income settings to greatly reduce severe disease and death outcomes. We only currently have data from the United States to inform levels of antiviral coverage and have used these data to update our scale-up model from last month. The model assumes individuals in high-income countries had been targeted for treatment, and access to treatment among this group had risen from 0% on March 15, 2022, to a maximum of 80% for high-risk individuals and 50% for low-risk individuals by June 1, 2022. This rollout assumption follows a similar pattern to global vaccine rollouts. Clinical trials suggest that Paxlovid provides an 88% reduction in the risk of hospitalization and death among people treated within five days of symptom onset. We made an additional assumption that if roughly 70% of deaths and 50% of admissions are incidental (defined as patients who test positive for COVID after being admitted to the hospital for other reasons), Paxlovid effectiveness among patients admitted primarily for COVID treatment would be 25-30% for deaths and 40-50% for admissions.

Lastly, we have made one alteration to our antiviral scenario assumptions in the model. Our scale-up model assumes that global distribution of antivirals will extend to all low- and middle-income countries between August 15, 2022, and September 15, 2022. Similar to the reference scenario, we assume a linear scale-up to a maximum of 80% access for high-risk individuals and 50% for low-risk individuals during this time frame.
Figure 1.1: Daily COVID-19 hospital census and estimated infections

Figure 2.1: Reported daily COVID-19 cases, moving average
Table 1: Ranking of total deaths due to COVID-19 among the leading causes of mortality this week, assuming uniform deaths of non-COVID causes throughout the year

<table>
<thead>
<tr>
<th>Cause name</th>
<th>Weekly deaths</th>
<th>Ranking</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischemic heart disease</td>
<td>503</td>
<td>1</td>
</tr>
<tr>
<td>Stroke</td>
<td>393</td>
<td>2</td>
</tr>
<tr>
<td>COVID-19</td>
<td>212</td>
<td>3</td>
</tr>
<tr>
<td>Tracheal, bronchus, and lung cancer</td>
<td>166</td>
<td>4</td>
</tr>
<tr>
<td>Alzheimer’s disease and other dementias</td>
<td>135</td>
<td>5</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease</td>
<td>115</td>
<td>6</td>
</tr>
<tr>
<td>Lower respiratory infections</td>
<td>115</td>
<td>7</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>89</td>
<td>8</td>
</tr>
<tr>
<td>Colon and rectum cancer</td>
<td>77</td>
<td>9</td>
</tr>
<tr>
<td>Hypertensive heart disease</td>
<td>58</td>
<td>10</td>
</tr>
</tbody>
</table>

Figure 3.1: Smoothed trend estimate of daily COVID-19 deaths
Daily COVID-19 death rate per 1 million on July 11, 2022

Figure 4.1: Daily reported COVID-19 death rate per 1 million

Figure 4.2: Daily total COVID-19 death rate per 1 million
Cumulative COVID-19 deaths per 100,000 on July 11, 2022

Figure 5.1: Reported cumulative COVID-19 deaths per 100,000

Figure 5.2: Total cumulative COVID-19 deaths per 100,000

Greece
Figure 6.1: Estimated percent of the population infected with COVID-19 on July 11, 2022

Figure 7.1: Mean effective R on June 30, 2022. Effective R less than 1 means that transmission should decline, all other things being held the same. The estimate of effective R is based on the combined analysis of deaths, case reporting, and hospitalizations where available. Current reported cases reflect infections 11-13 days prior, so estimates of effective R can only be made for the recent past.
Estimated percent of circulating SARS-CoV-2 for primary variant families on July 11, 2022

Figure 8.1: Estimated percent of new infections that are Alpha variant

Figure 8.2: Estimated percent of new infections that are Beta variant
Figure 8.3: Estimated percent of new infections that are Delta variant

Figure 8.4: Estimated percent of new infections that are Gamma variant
Figure 8.5: Estimated percent of new infections that are Omicron variant

- 0%
- 1−9%
- 10−24%
- 25−49%
- 50−74%
- 75−89%
- 90−100%

(covid19.healthdata.org Institute for Health Metrics and Evaluation)
Figure 9.1: Infection-fatality rate on July 11, 2022. This is estimated as the ratio of COVID-19 deaths to estimated daily COVID-19 infections.
### Critical drivers

#### Table 2: Current mandate implementation

| Country                  | Primary school closure | Secondary school closure | Higher school closure | Entry restrictions for some non-residents | Entry restrictions for all non-residents | Individual movements restricted | Individual curfew | Gathering limit: 6 indoor, 10 outdoor | Gathering limit: 10 indoor, 25 outdoor | Gathering limit: 25 indoor, 50 outdoor | Gathering limit: 50 indoor, 100 outdoor | Gathering limit: 100 indoor, 250 outdoor | Restaurants closed | Restaurants / bars closed | Restaurants / bars curbside only | Gyms, pools, other leisure closed | Non-essential retail closed | Non-essential workplaces closed | Stay home order | Stay home fine | Mask mandate | Mask mandate fine |
|--------------------------|------------------------|--------------------------|-----------------------|------------------------------------------|----------------------------------------|---------------------------------------|-------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|-----------------|------------------|-----------------------------|-----------------------------|-----------------------------|-------------------|---------------|--------------|----------------------|
| Greece                   |                        |                          |                       |                                          |                                        |                                       |                   |                                        |                                        |                                        |                                        |                                        |                 |                 |                             |                             |                             |                   |               |              |                       |
Figure 10.1: Trend in mobility as measured through smartphone app use, compared to January 2020 baseline
Figure 11.1: Mobility level as measured through smartphone app use, compared to January 2020 baseline (percent) on July 11, 2022
Figure 12.1: Trend in the proportion of the population reporting always wearing a mask when leaving home

Figure 13.1: Proportion of the population reporting always wearing a mask when leaving home on July 11, 2022
Figure 14.1: Trend in COVID-19 diagnostic tests per 100,000 people

Figure 15.1: COVID-19 diagnostic tests per 100,000 people on July 11, 2022
Table 3: Estimates of vaccine effectiveness for specific vaccines used in the model at preventing severe disease and infection. We use data from clinical trials directly, where available, and make estimates otherwise. More information can be found on our website.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Ancestral Severe disease</th>
<th>Ancestral Infection</th>
<th>Alpha Severe disease</th>
<th>Alpha Infection</th>
<th>Beta Severe disease</th>
<th>Beta Infection</th>
<th>Gamma Severe disease</th>
<th>Gamma Infection</th>
<th>Delta Severe disease</th>
<th>Delta Infection</th>
<th>Omicron Severe disease</th>
<th>Omicron Infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>AstraZeneca</td>
<td>94%</td>
<td>63%</td>
<td>94%</td>
<td>63%</td>
<td>94%</td>
<td>64%</td>
<td>94%</td>
<td>61%</td>
<td>94%</td>
<td>61%</td>
<td>94%</td>
<td>71%</td>
</tr>
<tr>
<td>CanSino</td>
<td>60%</td>
<td>62%</td>
<td>66%</td>
<td>62%</td>
<td>64%</td>
<td>61%</td>
<td>64%</td>
<td>61%</td>
<td>64%</td>
<td>61%</td>
<td>48%</td>
<td>32%</td>
</tr>
<tr>
<td>CoronaVac</td>
<td>50%</td>
<td>47%</td>
<td>50%</td>
<td>47%</td>
<td>49%</td>
<td>46%</td>
<td>49%</td>
<td>46%</td>
<td>49%</td>
<td>46%</td>
<td>37%</td>
<td>24%</td>
</tr>
<tr>
<td>Covaxin</td>
<td>78%</td>
<td>73%</td>
<td>78%</td>
<td>73%</td>
<td>76%</td>
<td>72%</td>
<td>76%</td>
<td>72%</td>
<td>76%</td>
<td>72%</td>
<td>57%</td>
<td>38%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
<td>86%</td>
<td>72%</td>
<td>86%</td>
<td>72%</td>
<td>76%</td>
<td>64%</td>
<td>76%</td>
<td>64%</td>
<td>76%</td>
<td>64%</td>
<td>57%</td>
<td>33%</td>
</tr>
<tr>
<td>Moderna</td>
<td>97%</td>
<td>92%</td>
<td>97%</td>
<td>92%</td>
<td>97%</td>
<td>91%</td>
<td>97%</td>
<td>91%</td>
<td>97%</td>
<td>91%</td>
<td>73%</td>
<td>48%</td>
</tr>
<tr>
<td>Novavax</td>
<td>89%</td>
<td>83%</td>
<td>89%</td>
<td>83%</td>
<td>86%</td>
<td>82%</td>
<td>86%</td>
<td>82%</td>
<td>86%</td>
<td>82%</td>
<td>86%</td>
<td>82%</td>
</tr>
<tr>
<td>Pfizer/BioNTech</td>
<td>95%</td>
<td>86%</td>
<td>95%</td>
<td>86%</td>
<td>95%</td>
<td>84%</td>
<td>95%</td>
<td>84%</td>
<td>95%</td>
<td>84%</td>
<td>72%</td>
<td>43%</td>
</tr>
<tr>
<td>Sinopharm</td>
<td>73%</td>
<td>68%</td>
<td>73%</td>
<td>68%</td>
<td>71%</td>
<td>67%</td>
<td>71%</td>
<td>67%</td>
<td>71%</td>
<td>67%</td>
<td>53%</td>
<td>35%</td>
</tr>
<tr>
<td>Sputnik-V</td>
<td>92%</td>
<td>86%</td>
<td>92%</td>
<td>86%</td>
<td>89%</td>
<td>85%</td>
<td>89%</td>
<td>85%</td>
<td>89%</td>
<td>85%</td>
<td>67%</td>
<td>44%</td>
</tr>
<tr>
<td>Other vaccines</td>
<td>75%</td>
<td>70%</td>
<td>75%</td>
<td>70%</td>
<td>73%</td>
<td>69%</td>
<td>73%</td>
<td>69%</td>
<td>73%</td>
<td>69%</td>
<td>55%</td>
<td>36%</td>
</tr>
<tr>
<td>Other vaccines (mRNA)</td>
<td>91%</td>
<td>86%</td>
<td>91%</td>
<td>86%</td>
<td>88%</td>
<td>85%</td>
<td>88%</td>
<td>85%</td>
<td>88%</td>
<td>85%</td>
<td>67%</td>
<td>45%</td>
</tr>
</tbody>
</table>
Percent of the population having received at least one dose (16.1) and fully vaccinated against SARS-CoV-2 (16.2) by July 11, 2022

**Figure 16.1: Percent of the population having received one dose of a COVID-19 vaccine**

**Figure 16.2: Percent of the population fully vaccinated against SARS-CoV-2**
Figure 17.1: Estimated proportion of the total population that is not vaccinated but willing to be vaccinated as of June 24, 2022
Figure 18.1: Percent of people who receive at least one dose of a COVID-19 vaccine and those who are fully vaccinated

![Graph showing percent of population vaccinated over time]

Figure 19.1: Percent of people who are immune to Delta or Omicron. Immunity is based on protection due to prior vaccination and infection(s). Moreover, variant-specific immunity is also based on variant-specific protection.

![Graph showing percent of population immune to Delta and Omicron over time]
Projections and scenarios

Figure 20.1: Daily COVID-19 infections until November 01, 2022 for three scenarios

Figure 20.2: Daily COVID-19 reported cases until November 01, 2022 for three scenarios
Figure 20.3: Daily COVID-19 hospital census until November 01, 2022 for three scenarios

- Reference
- Antiviral access
- 80% mask use
Figure 20.4: Reported daily COVID-19 deaths per 100,000
Figure 20.5: Total daily COVID-19 deaths per 100,000
Figure 21.1: Comparison of reference model projections with other COVID modeling groups. For this comparison, we are including projections of daily COVID-19 deaths from other modeling groups when available, last model update in brackets: Delphi from the Massachusetts Institute of Technology (Delphi) [July 18, 2022]. Regional values are aggregates from available locations in that region.
Figure 22.1: The estimated inpatient hospital usage is shown over time. The percent of hospital beds occupied by COVID-19 patients is color-coded based on observed quantiles of the maximum proportion of beds occupied by COVID-19 patients. Less than 5% is considered low stress, 5-9% is considered moderate stress, 10-19% is considered high stress, and 20% or greater is considered extreme stress.
Figure 23.1: The estimated intensive care unit (ICU) usage is shown over time. The percent of ICU beds occupied by COVID-19 patients is color-coded based on observed quantiles of the maximum proportion of ICU beds occupied by COVID-19 patients. Less than 10% is considered low stress, 10-29% is considered moderate stress, 30-59% is considered high stress, and 60% or greater is considered extreme stress.
More information

Data sources:

Mask use and vaccine confidence data are from the The Delphi Group at Carnegie Mellon University and University of Maryland COVID-19 Trends and Impact Surveys, in partnership with Facebook. Mask use data are also from Premise, the Kaiser Family Foundation, and the YouGov COVID-19 Behaviour Tracker survey.

Genetic sequence and metadata are primarily from the GISAID Initiative. Further details available on the COVID-19 model FAQ page.

A note of thanks:

We wish to warmly acknowledge the support of these and others who have made our COVID-19 estimation efforts possible.

More information:

For all COVID-19 resources at IHME, visit http://www.healthdata.org/covid.

To download our most recent results, visit our Data downloads page.